Rapamycin retards epigenetic ageing of keratinocytes independently of its effects on replicative senescence, proliferation and differentiation

• Published in: Aging (Albany, NY.) NY.), 2019-05, Vol.11 (10), p.3238-3249
• Main Authors: Horvath, Steve, Lu, Ake T, Cohen, Howard, Raj, Ken
• Format: Article
• Language: English
• Subjects: Aging - drug effects; Amides; Cell Differentiation; Cell Proliferation - drug effects; Cellular Senescence; Drug Evaluation, Preclinical; Epigenesis, Genetic - drug effects; Humans; Keratinocytes - drug effects; Primary Cell Culture; Pyridines; Research Paper; rho-Associated Kinases - antagonists & inhibitors; Sirolimus - pharmacology; Telomere Homeostasis; TOR Serine-Threonine Kinases - antagonists & inhibitors
• ISSN: 1945-4589; 1945-4589
• DOI: 10.18632/aging.101976

The advent of epigenetic clocks has prompted questions about the place of epigenetic ageing within the current understanding of ageing biology. It was hitherto unclear whether epigenetic ageing represents a distinct mode of ageing or a manifestation of a known characteristic of ageing. We report here that epigenetic ageing is not affected by replicative senescence, telomere length, somatic cell differentiation, cellular proliferation rate or frequency. It is instead retarded by rapamycin, the potent inhibitor of the mTOR complex which governs many pathways relating to cellular metabolism. Rapamycin, however, is also an effective inhibitor of cellular senescence. Hence cellular metabolism underlies two independent arms of ageing - cellular senescence and epigenetic ageing. The demonstration that a compound that targets metabolism can slow epigenetic ageing provides a long-awaited point-of-entry into elucidating the molecular pathways that underpin the latter. Lastly, we report here an assay, validated in humans, that recapitulates human epigenetic ageing that can be used to investigate and identify potential interventions that can inhibit or retard it.